产品信息 >> 蛋白相关 >> 重组蛋白;
Recombinant Human OPG, C-6His, Human cells

产品描述

概述

Recombinant Human Osteoprotegerin is produced by our Mammalian expression system and the target gene encoding Glu22-Leu401 is expressed with a 6His tag at the C-terminus.

使用说明

This material is offered by Novin Biotech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.

技术规格

TagC-6His
种属Human
表达系统Human cells
Accession#O00300
SourceHuman Cells
Formulation_DescriptionLyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.
StorageLyophilized protein should be stored at < -20°C, thoμgh stable at room temperature for 3 weeks.Reconstituted protein solution can be stored at 4-7°C for 2-7 days.Aliquots of reconstituted samples are stable at < -20°C for 3 months.
ReconstitutionDissolve the lyophilized protein in distilled water.
PurityGreater than 95% as determined by reducing SDS-PAGE.
EndotoxinLess than 0.1 ng/μg (1 EU/μg) as determined by LAL test.
BackgroundTNFRSF11B is a secreted protein, containing 2 death domains and 4 TNFR-Cys repeats. TNFRSF11B is a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL). By binding RANKL, TNFRSF11B inhibits nuclear kappa B (NF-κB) which is a central and rapid acting transcription factor for immune-related genes, and a key regulator of inflammation, innate immunity, and cell survival and differentiation. TNFRSF11B levels are influenced by voltage-dependent calcium channelsCav1.2. TNFRSF11B can reduce the production of osteoclasts by inhibiting the differentiation of osteoclast precursors (osteoclasts are related to monocytes/macrophages and are derived from granulocyte/macrophage-forming colony units (CFU-GM)) into osteoclasts and also regulates the resorption of osteoclasts in vitroand in vivo. TNFRSF11B binding to RANKL on osteoblast/stromal cells, blocks the RANKL-RANK ligand interaction between osteoblast/stromal cells and osteoclast precursors. This has the effect of inhibiting the differentiation of the osteoclast precursor into a mature osteoclast.
Biological_ActivityMeasured by its ability to inhibit TRAIL-mediated cytotoxicity using L 929 mouse fibroblast cells treated with TRAIL. The ED50 for this effect is 2-10 ng/ml.
上一篇:Recombinant Human SP
下一篇:Recombinant Human TN
关于我们 | 产品信息 | 技术服务 | 联系我们

     电话:400-832-8698    地址:北京怀柔雁栖开发区光织谷东区二号楼 

   备案/许可证编号京ICP备2020036913号